Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on April 27, 2020, with the earliest event reported dated April 12, 2020. The filing primarily addresses the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $385,000 per year for the new Chief Medical Officer.
- Stock Option Grant: 85,500 shares with an exercise price of $6.59 per share.
- Restricted Stock Units (RSUs): 20,000 RSUs granted immediately; 120,000 RSUs contingent upon a Change of Control.
Material Changes
The material change reported is the appointment of Efthymios Deliargyris, M.D., as Chief Medical Officer, effective May 1, 2020. Dr. Deliargyris brings significant experience in cardiovascular medicine and biotech leadership, having previously served as Chief Medical Officer at PLx Pharma Inc. and Global Medical Lead at The Medicines Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the vesting of equity awards, which is subject to Dr. Deliargyris's continued employment and, in the case of 120,000 RSUs, the occurrence of a Change of Control. The employment agreement includes standard covenants regarding non-competition and confidentiality.
Investor Verification Checklist
- Verify the effective start date of the new Chief Medical Officer (May 1, 2020).
- Review the vesting schedule for the 85,500 stock options (30,000 vesting Oct 12, 2020; remainder over three years).
- Confirm the terms of the 120,000 Change of Control RSUs as defined in the Employment Agreement (Exhibit 10.1).
- Check for any potential dilution impact from the 105,500 total equity units granted (options and RSUs).